



Figure 1. MALDI-TOF mass spectra (top) and HPLC traces (bottom) for the Q11 and GlcNAc-Q11 peptides used in this study.



Figure 2. ThT fluorescence versus concentration of Q11 in PBS.



Figure 3. Scatter plots of CD80 and CD86 expression by untreated DCs, LPS-treated DCs, and Q11 microgel-treated DCs.



Figure 4. Burst release profile of sfGFP from Q11 microgels. "3x loading" denotes microgels fabricated from 1 mM Q11 nanofibers mixed with 141 μ g sfGFP prior to desolvation, "1x loading" denotes microgels fabricated from 1 mM Q11 nanofibers mixed with 47 μ g sfGFP prior to desolvation.



Figure 5. SDS-PAGE analysis of WGA in Q11/GlcNAc-Q11 microgels lysed with TFA.



Figure 6. Apoptosis of Jurkat T cells, as determined via protease activity, by Q11 microgels. 10,000 cells were treated with PBS (control) or 600 μ M empty Q11 microgels for 4 h. Jurkat protease activity, a measure of cell viability, was determined with the CellTiter-Fluor reagent (Promega, Madison, WI) according to the manufacturer's instructions. n.s. represents p > 0.05 between groups, n = 3.



Figure 7. Release profile of WGA from Q11 microgels with 0% GlcNAc-Q11 (circles) or 25% GlcNAc-Q11 (diamonds), n = 3.